COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives Average Rating of “Moderate Buy” from Analysts

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) has earned a consensus rating of “Moderate Buy” from the ten research firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $16.1111.

CMPS has been the subject of several research reports. Lifesci Capital upgraded shares of COMPASS Pathways to a “strong-buy” rating in a research note on Thursday, February 12th. Compass Point set a $15.00 price target on COMPASS Pathways in a research report on Thursday, February 12th. Royal Bank Of Canada lifted their target price on COMPASS Pathways from $16.00 to $21.00 and gave the company an “outperform” rating in a research note on Friday, January 23rd. Morgan Stanley increased their price objective on shares of COMPASS Pathways from $10.00 to $11.00 and gave the company an “overweight” rating in a report on Wednesday, November 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of COMPASS Pathways in a research report on Wednesday, January 21st.

COMPASS Pathways News Summary

Here are the key news stories impacting COMPASS Pathways this week:

• Positive Sentiment: COMP360 met the primary endpoint in a late‑stage (Phase 3) study, driving optimism about regulatory and commercial prospects for the psilocybin therapy. This is the main catalyst for the rally. Compass Pathways’ depression treatment meets main goal in late‑stage study
• Positive Sentiment: Compass announced it will report new clinical data from two ongoing Phase 3 trials (COMP005 and COMP006) and provided a timeline for additional Phase 3 results, reinforcing near‑term news flow that supports further upside. Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials
• Positive Sentiment: Market activity shows heightened bullish positioning: unusually large call option volume (over 10,000 calls) and extremely heavy equity volume suggest speculative and institutional buying around the trial news, which amplified the stock move. (Internal trading/activity reports)
• Neutral Sentiment: Public and media coverage (Investing.com, PharmaLetter, MSN) amplified investor attention; press coverage supports momentum but doesn’t guarantee regulatory approval or commercial success. Compass Pathways stock soars after positive Phase 3 trial results
• Neutral Sentiment: Reported short‑interest data in the filings appears erroneous (0 shares / NaN changes) and is unreliable as an indicator of bearish positioning or squeeze potential at present.
• Neutral Sentiment: Third‑party analyst commentary and forecasts (e.g., Lifesci Capital coverage) exist but are secondary to the actual trial readouts for near‑term price action. What is Lifesci Capital’s Forecast for CMPS FY2025 Earnings?
• Negative Sentiment: Compass launched a proposed $150M public offering of ADSs (and pre‑funded warrants), which can dilute existing shareholders and may cap near‑term upside despite the positive data. Investors should weigh dilution risk against trial progress. Compass Pathways Launches Proposed $150.0 Million Public Offering

COMPASS Pathways Stock Performance

CMPS stock opened at $7.63 on Wednesday. The firm has a 50 day simple moving average of $6.77 and a 200 day simple moving average of $5.89. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.23 and a current ratio of 1.23. COMPASS Pathways has a 52 week low of $2.25 and a 52 week high of $8.80. The stock has a market cap of $732.63 million, a P/E ratio of -2.81 and a beta of 1.92.

Hedge Funds Weigh In On COMPASS Pathways

A number of large investors have recently modified their holdings of the business. Persistent Asset Partners Ltd acquired a new position in COMPASS Pathways during the fourth quarter worth $38,000. Advisory Services Network LLC bought a new stake in shares of COMPASS Pathways during the third quarter worth approximately $41,000. BIT Capital GmbH acquired a new position in COMPASS Pathways in the 3rd quarter valued at $54,000. MML Investors Services LLC acquired a new position in shares of COMPASS Pathways in the fourth quarter valued at about $69,000. Finally, Magnetar Financial LLC bought a new position in shares of COMPASS Pathways during the fourth quarter worth approximately $91,000. 46.19% of the stock is currently owned by institutional investors and hedge funds.

COMPASS Pathways Company Profile

COMPASS Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, COMPASS Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.